Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.

Senn C, Günther B, Popp AW, Perrelet R, Hans D, Lippuner K

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA24 Apr 2014Cited by 69 (Europe PMC)

PMID24760244DOI10.1007/s00198-014-2703-8PepBankPUB-24760244

Publisher page PubMedAsk about this study

Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

01HumanObservational studyEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide was linked to a larger lumbar spine BMD increase than ibandronate.
In plain wordsIn women with osteoporosis, teriparatide was linked to a larger spine BMD increase than ibandronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n = 187
Comparator
Ibandronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 2 yearsAs given in this study (human).
Measurements
Lumbar spine BMD increase
7.6%
teriparatide
Lumbar spine BMD increase
2.9%
ibandronate
Source sentences
Summary
Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6 % ± 6.3 vs. +2.9 % ± 3.3 and +4.3 % ± 6.6 vs. +0.3 % ± 4.1, respectively; P < 0.0001 for both).
1 context sentence(design, population, supporting numbers)
Summary · context
Two patient groups with matched age, body mass index (BMI), and baseline LS BMD, treated with either daily subcutaneous teriparatide (N = 65) or quarterly intravenous IBN (N = 122) during 2 years and with available LS BMD measurements at baseline and 2 years after treatment initiation were compared.
Report a problemFND-2476024401
02HumanObservational studyEfficacy outcome
In postmenopausal women with osteoporosis, teriparatide was linked to a larger trabecular bone score increase than ibandronate.
In plain wordsIn women with osteoporosis, teriparatide was linked to a larger trabecular bone score increase than ibandronate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseTrabecular bone score
Study
n = 187
Comparator
Ibandronate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
Dose not stated · subcutaneous · 2 yearsAs given in this study (human).
Measurements
TBS increase
4.3%
teriparatide
TBS increase
0.3%
ibandronate
Source sentences
Summary
Over 24 months, teriparatide induced a significantly larger increase in LS BMD and TBS than IBN (+7.6 % ± 6.3 vs. +2.9 % ± 3.3 and +4.3 % ± 6.6 vs. +0.3 % ± 4.1, respectively; P < 0.0001 for both).
1 context sentence(design, population, supporting numbers)
Summary · context
Two patient groups with matched age, body mass index (BMI), and baseline LS BMD, treated with either daily subcutaneous teriparatide (N = 65) or quarterly intravenous IBN (N = 122) during 2 years and with available LS BMD measurements at baseline and 2 years after treatment initiation were compared.
Report a problemFND-2476024402

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.